Uptake of PCV13 Low Among Seniors — Physician’s First Watch
Uptake of PCV13 Low Among Seniors
By Kelly Young
Two years after the CDC began recommending that seniors get the 13-valent pneumococcal conjugate vaccine (PCV13), many hadn't received it, according to an MMWR article.
In 2014, the agency recommended that adults aged 65 and older receive the PCV13 vaccine in a series with the previously recommended 23-valent pneumococcal polysaccharide vaccine (PPSV23). Using Medicare claims data, researchers found that by 2016, 43% of beneficiaries had received at least one dose of PPSV23, 32% had received at least one PCV13 dose, and 18% had received both.
Pneumococcal vaccination was more common among patients who were older, were white, or had chronic medical conditions.
The authors note that up to 25% of cases of invasive pneumococcal disease in seniors are caused by serotypes covered only by PCV13.